Table 1 Association between mutational status and clinicopathological findings.

From: TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors

Genotype

No BRAF, no TERT (1)

BRAF mut (2)

BRAF/TERT mut (3)

p-value (1 vs 2)

p-value (2 vs 3)

p-value (1 vs 3)

Number of cases

62 (17.4%)

258 (72.5%)

36 (10.1%)

 

Age (mean ± s.d.)

45.8 ± 16.6

49.7 ± 14.6

70.1 ± 8.3

0.259 a

<0.001a

<0.001a

Sex (F/M, % male)

57/5 (8.1%)

218/40 (15.5%)

28/8 (22.2%)

ns b

ns b

ns b

Tumor size (mean ± s.d.)

22.6 ± 15.3

19.8 ± 11.4

32.1 ± 15.7

0.445 a

<0.001 a

0.014 a

LN metastasis

34/61 (55.7%)

167/258 (64.7%)

20/36 (55.6%)

ns b

ns b

ns b

Distant metastasis d

0

1 (0.4%)

5 (13.9%)

n/p

<0.05b

n/p

Stage c

   

<0.05b

<0.05b

<0.05b

 

I

37

114

2

   

II

3

5

0

III

16

99

16

IV

6

40

18

Ex

41 (66.1%)

189 (73.3%)

33 (91.7%)

ns b

<0.05b

<0.05b

  1. ns: not significant, p ≥ 0.05.
  2. n/p: not performed.
  3. aNon-parametric ANOVA with Dunnett post hoc test.
  4. bMultiple comparison test for proportions (using the COMPROP procedure in SAS http://www2.sas.com/proceedings/sugi31/204-31.pdf).
  5. cCalculations for Stage (I + II) vs. (III + IV).
  6. dAll metastatic sites were the lung.
Back to article page